ATE442161T1 - Botulinumneurotoxin-b-rezeptoren und ihreverwendung - Google Patents

Botulinumneurotoxin-b-rezeptoren und ihreverwendung

Info

Publication number
ATE442161T1
ATE442161T1 AT03816739T AT03816739T ATE442161T1 AT E442161 T1 ATE442161 T1 AT E442161T1 AT 03816739 T AT03816739 T AT 03816739T AT 03816739 T AT03816739 T AT 03816739T AT E442161 T1 ATE442161 T1 AT E442161T1
Authority
AT
Austria
Prior art keywords
bont
syt
methods
binding
disclosed
Prior art date
Application number
AT03816739T
Other languages
German (de)
English (en)
Inventor
Edwin Chapman
Min Dong
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Application granted granted Critical
Publication of ATE442161T1 publication Critical patent/ATE442161T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03816739T 2002-10-31 2003-10-28 Botulinumneurotoxin-b-rezeptoren und ihreverwendung ATE442161T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42295102P 2002-10-31 2002-10-31
US49812803P 2003-08-27 2003-08-27
PCT/US2003/034348 WO2005016233A2 (en) 2002-10-31 2003-10-28 Botulinum neurotoxin b receptors and use thereof

Publications (1)

Publication Number Publication Date
ATE442161T1 true ATE442161T1 (de) 2009-09-15

Family

ID=34197667

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03816739T ATE442161T1 (de) 2002-10-31 2003-10-28 Botulinumneurotoxin-b-rezeptoren und ihreverwendung

Country Status (10)

Country Link
US (2) US20040191887A1 (enExample)
EP (1) EP1578382B1 (enExample)
JP (2) JP2006512090A (enExample)
AT (1) ATE442161T1 (enExample)
AU (1) AU2003304419A1 (enExample)
CA (1) CA2504532C (enExample)
DE (1) DE60329225D1 (enExample)
ES (1) ES2333319T3 (enExample)
IL (1) IL167943A (enExample)
WO (1) WO2005016233A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1578382B1 (en) * 2002-10-31 2009-09-09 Wisconsin Alumni Research Foundation Botulinum neurotoxin b receptors and use thereof
US7341843B2 (en) * 2003-04-11 2008-03-11 Allergan, Inc. Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
WO2006113648A2 (en) * 2005-04-18 2006-10-26 University Of Massachusetts Hn-33 compositions and methods
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
US7985554B2 (en) 2005-10-14 2011-07-26 Wisconsin Alumni Research Foundation Botulinum neurotoxin A receptor and the use thereof
DE102005051789B4 (de) 2005-10-28 2014-08-07 Toxogen Gmbh Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen
CN101932936B (zh) 2007-09-14 2016-04-27 拜奥麦迪逊公司 利用切割序列和间隔子的共振能量转移测定
US10908146B2 (en) 2011-06-01 2021-02-02 Biomadison, Inc. Compositions and methods for improving sensitivity in cell based assays
US9303285B2 (en) 2012-01-04 2016-04-05 Biomadison, Inc. Methods and compounds for increasing sensitivity of botulinum assays
US12422428B2 (en) 2011-06-01 2025-09-23 Biomadison, Inc. Compositions and methods for cell-based assays
LT2715355T (lt) 2011-06-01 2017-06-12 Biomadison, Inc. Ne fret (fluorescencijos rezonansinės energijos perdavimas) būdu atliekamas botulino tyrimas
US11325954B2 (en) 2011-06-01 2022-05-10 Biomadison, Inc. Compositions and methods for stability testing of botulinum toxin
WO2015021433A1 (en) 2013-08-09 2015-02-12 Biomadison, Inc. Botulinum toxin assay with improved sensitivity
JPWO2023210585A1 (enExample) * 2022-04-25 2023-11-02

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6994995B1 (en) * 2001-03-16 2006-02-07 Lexicon Genetics Incorporated Human synaptotagmin and polynucleotides encoding the same
US8022172B2 (en) * 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
EP1578382B1 (en) * 2002-10-31 2009-09-09 Wisconsin Alumni Research Foundation Botulinum neurotoxin b receptors and use thereof
EP1751284A4 (en) * 2003-12-19 2010-01-13 Wisconsin Alumni Res Found METHOD AND COMPOSITIONS FOR DETECTING BOTULINUM NEUROTOXINE
EP1920248B1 (en) * 2005-04-05 2010-09-29 Allergan, Inc. Clostridial toxin activity assays
AU2006299933A1 (en) * 2005-08-02 2007-04-19 Planet Biotechnology, Inc. Improved chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
US7985554B2 (en) * 2005-10-14 2011-07-26 Wisconsin Alumni Research Foundation Botulinum neurotoxin A receptor and the use thereof
WO2013011055A1 (en) * 2011-07-19 2013-01-24 ETH Zürich Means and methods for determining clostridial neurotoxins

Also Published As

Publication number Publication date
EP1578382A4 (en) 2007-08-29
EP1578382B1 (en) 2009-09-09
US8617573B2 (en) 2013-12-31
WO2005016233A3 (en) 2005-08-18
EP1578382A2 (en) 2005-09-28
US20120082672A1 (en) 2012-04-05
ES2333319T3 (es) 2010-02-19
JP2006512090A (ja) 2006-04-13
CA2504532A1 (en) 2005-02-24
AU2003304419A1 (en) 2005-03-07
CA2504532C (en) 2014-09-16
AU2003304419A8 (en) 2005-03-07
WO2005016233A2 (en) 2005-02-24
US20040191887A1 (en) 2004-09-30
DE60329225D1 (de) 2009-10-22
IL167943A (en) 2010-12-30
JP2010006833A (ja) 2010-01-14

Similar Documents

Publication Publication Date Title
ATE442161T1 (de) Botulinumneurotoxin-b-rezeptoren und ihreverwendung
CY1122686T1 (el) Ανταγωνιστικοι εκλεκτικοι παραγοντες συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης
EP1687283A4 (en) FOR THE DETERMINATION OF FK506 PROCEDURE AND COMPOSITION
ATE466080T1 (de) Formulierungen und verfahren zum denaturieren von proteinen
DE602004006433D1 (de) Pyrrol-substituierte indole als inhibitoren von pai-1
ATE227739T1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
ATE480643T1 (de) Homogener nachweis von analyten
ATE544473T1 (de) Chimäre moleküle zur modulation der genexpression
DE69919537D1 (de) Arylsubstituierte olefinische amine und ihre verwendung als cholinergische rezeptoragonisten
DE60100620D1 (de) Gezielte elektrochemische reduktion von halogenierten 4-amino-picolinsäuren
ATE439441T1 (de) Veränderte, fluoreszierende proteine
DE602005016800D1 (de) Hif-prolylhydroxylase-aktivitätstest
ATE466283T1 (de) Zentrifugalvorrichtung und verfahren zur durchführung von bindungsversuchen
DE60129137D1 (de) Modulierung durch il-tif/interleukin-21
DE60107416D1 (de) Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion
ATE487792T1 (de) Verfahren und zusammensetzungen zur identifikation von rna-bindenden proteinen
DK1064018T3 (da) Anvendelsen af isolerede domæner af Type IV kollagen til at modificere celle- og vævsinteraktioner
DE602004026893D1 (de) Rung und zum nachweis von mikroorganismen
EA200401032A1 (ru) Антиинфарктные молекулы
DE60332479D1 (de) Holo-transcobalamin bindungspartner und ihre verwendung in cobalamintest
DE50311665D1 (de) Guanidinophenylalanin-verbindungen als urokinase-inhibitoren
ATE540047T1 (de) Gedächtnisveränderung durch beeinflussung der funktion von staufen
WO2002095354A3 (en) Methods and labeled molecules for determining ligand binding to steroid receptors
ATE382098T1 (de) Zellbindende nukleinsäuremoleküle (aptamere)
DE69535039D1 (de) Cytoplasmische tyrosin kinase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties